Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
DRopEridol for Abdominal pain in the emergency department for Morphine Equivalent Reduction. The DREAMER study.
Am J Emerg Med
January 2025
Pharmacy Department, Wesley Medical Center, 550 N Hillside St, Wichita, KS 67214, United States of America.
Introduction: Droperidol is a dopamine-2 receptor antagonist in the class of butyrophenone antipsychotics with antiemetic, sedative, analgesic, and anxiolytic properties. In the postoperative setting, droperidol provides an opioid sparing effect and decreases nausea/vomiting. Another butyrophenone antipsychotic, haloperidol, has been shown to reduce morphine milliequivalents (MME) administered when used for abdominal pain in the emergency department (ED).
View Article and Find Full Text PDFIncidence and influential factors of postoperative pruritus in morphine-based intravenous patient-controlled analgesia.
J Chin Med Assoc
October 2024
Department of Anesthesiology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, ROC.
Background: Pruritus is a distressing symptom of systemic opioid analgesia that responds poorly to conventional antipruritus treatments. This study aimed to determine the incidence and risk factors for postoperative pruritus using intravenous patient-controlled analgesia (IV-PCA).
Methods: Opioid-naïve patients who underwent morphine-based IV-PCA for postoperative pain at a tertiary center between January 1, 2020, and June 30, 2023, were included retrospectively.
Evaluation of droperidol use in the emergency department: a retrospective analysis of QTc prolongation and adverse events.
BMC Emerg Med
December 2024
Department of Pharmacy Services, Brigham and Women's Hospital, Boston, MA, USA.
Background: Droperidol is a first-generation antipsychotic medication that has been used for various indications in the emergency department (ED); however, its use has been controversial due to reports of QT prolongation and the risk of torsades de pointes (TdP). The aim of the study is to evaluate the safety of droperidol administration in the ED.
Methods: This was a retrospective study, conducted at an academic level I trauma center.
Rescue Sedation after 5 mg or 10 mg of Droperidol as the Initial Treatment for Acute Agitation in the Emergency Department.
J Emerg Med
January 2025
Department of Emergency Medicine, Hennepin Healthcare, Minneapolis, Minnesota.
Article Synopsis
- The study aimed to compare the effectiveness of 5 mg vs. 10 mg droperidol for treating acute agitation in emergency department patients.
- A total of 11,568 adult patients were analyzed, with 10,293 receiving 5 mg and 1,275 receiving 10 mg of droperidol, finding that 14.8% of patients on the 10 mg dose needed additional sedation compared to 9.6% on the 5 mg dose.
- The results suggest that the 5 mg dose may be more effective, as it led to lower rates of rescue sedation within one hour.
Comparing the cardiorespiratory safety of parenteral olanzapine and benzodiazepines to parenteral haloperidol/droperidol and benzodiazepines in emergency department patients.
Am J Emerg Med
January 2025
Upstate University Hospital, Department of Pharmacy, 750 East Adams Street, Syracuse, NY, USA.
Introduction: This study sought to assess the cardiorespiratory safety of parenteral olanzapine and benzodiazepine combination treatment compared to parenteral droperidol or haloperidol and benzodiazepine combination treatment.
Materials And Methods: This was a retrospective chart review conducted in adult emergency department patients who received intramuscular (IM) or intravenous (IV) droperidol, haloperidol, or olanzapine within one hour of IM or IV benzodiazepine. Patients were stratified into groups based on whether they received either olanzapine in combination with a benzodiazepine (n = 48) or droperidol or haloperidol in combination with a benzodiazepine (n = 48).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!